Carlyle leads $123m round in Shanghai-based biopharma firm Abbisko
Premium
Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery and preclinical development stages.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief
Opt out of receiving The Daily Brief in your inbox everyday
REGISTER
stories_left_placeholder
You have one free story left this month.
You have stories_left_placeholder free stories left this month.